Barinthus Biotherapeutics reported a passive-stake amendment covering 8,797,770 shares at $0.11 per share. For investors, the ownership record lists Oxford Science Enterprises plc at 0.0%, while the securities are American Depositary Shares representing ordinary shares. The transaction record was signed by Oxford’s chief financial officer.

Key Highlights

  • Oxford Science Enterprises plc’s ownership record lists 0.0% and zero shares.
  • Antonia Jenkinson, Oxford Science Enterprises’ chief financial officer, signed the record on September 11, 2026.
  • Passive-stake amendment tied to a transaction involving 8,797,770 shares.

Barinthus Biotherapeutics plc. reported a passive-stake amendment tied to a transaction involving 8,797,770 shares at $0.11 per share. Oxford Science Enterprises plc is the named reporting party.

Passive-Stake Amendment Covers 8,797,770 Shares

The ownership record identifies Oxford Science Enterprises plc and lists its position at zero shares and 0.0%. The document carries a September 9, 2026 date. The transaction record describes Oxford Science Enterprises as an insider of Barinthus Biotherapeutics and assigns the transaction a price of $0.11 per share. Antonia Jenkinson, Oxford’s chief financial officer, signed the record on September 11, 2026.